Plus   Neg

Eli Lilly Announces Several Leadership Changes - Quick Facts

Eli Lilly and Co. (LLY) announced Wednesday several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations.

The company said Darren Carroll, senior vice president of corporate business development, will retire at the end of August after 22 years of service with the company.

Carroll will be succeeded by Heather Wasserman with responsibility for business development transactions, emerging technologies and innovation, and venture capital.

Meanwhile, Phil Johnson, senior vice president and treasurer, will assume additional duties overseeing merger & acquisition activity.

Levi Garraway has resigned from his position as senior vice president of oncology research and early phase development in order to pursue other opportunities. Garraway will be succeeded by Josh Bilenker, CEO of Loxo Oncology, on an interim basis.

Additionally, Frank Cunningham has been promoted to senior vice president of managed healthcare services.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT